2009
The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.
Hernandez-Ilizaliturri F, Marvis C, Maraj I, Chisti M, Gibbs J, Czuczman M. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009, 114: 2715. DOI: 10.1182/blood.v114.22.2715.2715.Peer-Reviewed Original ResearchPatient-derived primary tumor cellsB-cell lymphomaPrimary tumor cellsChemotherapy agentsAnti-tumor activityMonoclonal antibodiesTumor cellsPolymerase chain reactionLymphoma cell linesCell linesAnti-CD20 Monoclonal AntibodyRoswell Park Cancer InstituteLarge B-cell lymphomaState Cancer CenterCD20 monoclonal antibodySignificant anti-tumor activitySequence of administrationQualitative polymerase chain reactionAnti-tumor effectsPotent treatment strategyNHL cell linesCombination of LBH589Primary lymphoma cellsResistant cell linesSensitive cell lines
2008
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection